Whitehawk Therapeutics (WHWK)
Develops in-licensed antibody-drug conjugates for cancer treatment.
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know
The mean of analysts' price targets for Whitehawk Therapeutics, Inc. (WHWK) points to a 47.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cash equivalents and short-term investments of $190.0 million as of June 30, 2026, anticipated to fund operations into 2H 2028 MORRISTOWN, N.J., Aug. 6, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended June 30, 2026, and provided recent corporate highlights.
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics Presents RealâWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neur
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
MORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual Targeted Oncology Forum on Tuesday, May 19, 2026, at 3 PM ET.
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
MORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $87.5 million, before deducting placement agent fees and other private placement expenses.
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 Cash, cash equivalents and short-term investments balance of $123.0 million as of March 31, 2026, anticipated to fund operations into 2028 MORRISTOWN, N.J., May 7, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended March 31, 2026, and provided recent corporate highlights.
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the Jones Trading Post-AACR Fireside Chat Series on Thursday, April 23, 2026, at 3 PM ET.
David James Lennon Sells 26,858 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) CEO David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.48, for a total value of $93,465.84. Following the sale, the chief executive officer directly owned 793,549 shares
Ally Bridge Group NY LLC Takes $1.55 Million Position in Whitehawk Therapeutics, Inc. $WHWK
Ally Bridge Group NY LLC acquired a new stake in Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 817,939 shares of the company's stock, valued at approximately $1,554,000. Whitehawk Therapeutics accounts for 0.9%
2,849,402 Shares in Whitehawk Therapeutics, Inc. $WHWK Purchased by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC acquired a new position in shares of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,849,402 shares of the company's stock, valued at approximately $5,414,000. Whitehawk Therapeutics comprises 0.1% of Avoro
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16-targeted ADC HWK-016 HWK-206 on track for planned IND submission in mid-2026 and Phase 1 start in Q3 Cash, cash equivalents and short-term investments balance of $145.7M at YE2025, anticipated to fund operations into 2028 MORRISTOWN, N.J., March 12, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided recent corporate highlights.
Contrasting Whitehawk Therapeutics (NASDAQ:WHWK) & Vincerx Pharma (NASDAQ:VINC)
Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) and Vincerx Pharma (NASDAQ: VINC - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings. Analyst Recommendations This is a breakdown of
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J., Feb. 26, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences: TD Cowen 46th Annual Health Care Conference – Dave Lennon, PhD, President and CEO, will participate in a hybrid presentation and fireside chat on Tuesday, March 3 at 10:30 AM ET Leerink 2026 Global Healthcare Conference – executives will participate in investor meetings on Monday, March 9 Citizens Life Sciences Conference – Dave Lennon, PhD, President and CEO, will give a corporate presentation on Tuesday, March 10 at 12:30 PM ET A live webcast of the TD Cowen and Citizens presentations can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
Whitehawk Therapeutics (NASDAQ:WHWK) versus IMV (OTCMKTS:IMVIQ) Financial Review
IMV (OTCMKTS:IMVIQ - Get Free Report) and Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Valuation and Earnings This table compares IMV and
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
Actively recruiting Phase 1 trial for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 IND submitted mid-December 2025 for MUC16-targeted ADC HWK-016, anticipated Phase 1 start this quarter Initial clinical data from both programs anticipated in early 2027 MORRISTOWN, N.J., Jan. 8, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for HWK-007, its PTK7-targeted ADC.
Comparing Whitehawk Therapeutics (NASDAQ:WHWK) & Acerus Pharmaceuticals (OTCMKTS:TRLPF)
Acerus Pharmaceuticals (OTCMKTS:TRLPF - Get Free Report) and Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation. Profitability This table compares Acerus Pharmaceuticals and
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J. , Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer (CMO).
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
MORRISTOWN, N.J. , Nov. 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City, NY on December 3, 2025, at 12:30 PM ET.
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
MORRISTOWN, N.J. , Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the third quarter ended September 30, 2025, and provided recent corporate progress.
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J. , Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat during the following upcoming investor conferences in New York City, NY: Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025.